Healthcare Industry News: Cytogen
News Release - September 11, 2007
NCCN Updates Dermatofibrosarcoma Protuberans GuidelinesJENKINTOWN, Pa.--(HSMN NewsFeed)--The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Dermatofibrosarcoma Protuberans (DFSP) Guidelines. DFSP is a rare, low-grade sarcoma characterized by a t(17;22) chromosomal translocation resulting in the over-expression of platelet-derived growth factor receptor-beta (PDGFRB). This abnormal proliferation of cells can quickly grow into a malignant tumor.
In a phase II open-label trial--Study B2225, the largest study involving patients with DFSP)--imatinib mesylate, an inhibitor of PDGFRB, was found to be safe and effective in the treatment of patients with locally advanced and metastatic DFSP tumors containing t(17;22) translocation. Based on the results of this study and five other published case reports, the FDA approved imatinib mesylate for the treatment of adult patients with unresectable, recurrent and/or metastatic DFSP.
In response to the favorable results and the FDA approval, the NCCN DFSP Guidelines now include imatinib mesylate (GleevecŪ, Novartis Pharmaceuticals) as an option for patients with DFSP with the following indications:
(i) positive surgical margins following re-resection, if further resection is not feasible
(ii) recurrent disease, if additional resection would lead to unacceptable functional or cosmetic outcomes
(iii) metastatic disease.
Study B2225 also showed that patients with DFSP lacking t(17;22) may not respond to imatinib. As a result, the guidelines suggest that molecular analysis of a tumor using Cytogenetics may be useful prior to the institution of imatinib therapy.
The NCCN Clinical Practice Guidelines in Oncology(TM) are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. These guidelines are developed and continually updated through an evidence-based process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN Member Institutions. The most recent version of this and all the guidelines are available free of charge at www.nccn.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
For more information, visit www.nccn.org.
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.